Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
BHC Q3 Earnings Preview: Here's What You Should Know
26.10.2026 17:33
Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2
26.10.2026 13:45
Vertex Pharmaceuticals (NASDAQ:VRTX) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. Diversification Picks Up Speed After a Raised Outlook Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS […]
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
26.10.2026 13:00
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept
25.10.2026 03:19
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...
What Vertex Pharmaceuticals Holders Bought Into
25.10.2026 02:09
If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
24.10.2026 03:27
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
24.10.2026 03:02
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm
How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs
23.10.2026 12:00
Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots
Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?
21.10.2026 15:19
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]
Why Should You Think About Vertex Differently Now?
21.10.2026 00:56
Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time
What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders
18.10.2026 15:12
Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...
3 Top Quality Value Stocks To Watch In October 2026
14.10.2026 11:11
Rising gasoline and diesel costs are pushing US inflation higher, and that puts steady cash generation and conservative balance sheets back in the spotlight. When borrowing stays expensive and prices keep climbing, investors often pay closer attention to companies that already throw off cash and carry less debt. This article breaks down three such undervalued high quality stocks and explains why they might deserve a spot on your watchlist now. The stocks highlighted below are just a small...
2 High-Flying Stocks on Our Watchlist and 1 We Question
12.10.2026 10:31
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
06.10.2026 06:13
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
06.10.2026 06:13
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
05.10.2026 12:00
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project
05.10.2026 12:00
Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potentialVANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons Ri
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
03.10.2026 02:40
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
01.10.2026 19:17
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
29.09.2026 00:37
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]